News AMD shadows NVIDIA with a move into AI drug discovery Chipmaker AMD has taken a 20% stake in Absci, a specialist in the use of artificial intelligence in for biologic drug discovery.
News AstraZeneca links with Absci on AI for biologics discovery AstraZeneca has agreed a deal worth up to $247 million with US generative artificial intelligence (GenAI) company Absci that will focus on the discovery of a new antibody-
News Changing Faces: pharma supplier, DTx, and non-profit hires f... A number of pharma-adjacent tech firms and non-profits announced personnel news in the month of November. We’ve rounded up some highlights below.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
